Intravenous treatment with a molecular chaperone designed against β-amyloid toxicity improves Alzheimer’s disease pathology in mouse models
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a single point mutation, R221E, within the BRI2 BRICHOS domain has been shown to favor the monomeric form and exhibits greater efficacy than wild-type BRI2 BRICHOS in mitigating Aβ42-mediated neurotoxicity in mouse hippocampal slices (Chen et al, 2020; Manchanda et al, 2023).”
From Functional BRI2-TREM2 interactions in microglia: implications for Alzheimer’s and related dementias (2024) · cites this paper as Manchanda et al, 2023
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Single-cell transcriptomic analysis of Alzheimer’s disease
Mathys, H., Davila-Velderrain, J., Peng, Z., Gao, F., Mohammadi, S., Young, J. Z., Menon, M., He, L., Abdurrob, F., Jiang, X., et al. (2019) · Nature · doi:10.1038/s41586-019-1195-2 · Cited by 2,568
A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738
Defeating Alzheimer's disease and other dementias: a priority for European science and society
Winblad, B., Amouyel, P., Andrieu, S., Ballard, C., Brayne, C., Brodaty, H., Cedazo-Minguez, A., Dubois, B., Edvardsson, D., Feldman, H., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00062-4 · Cited by 1,676
The proteostasis network and its decline in ageing
Hipp, M. S., Kasturi, P., & Hartl, F. U. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0101-y · Cited by 1,642
Single App knock-in mouse models of Alzheimer’s disease
Saito, T., Matsuba, Y., Mihira, N., Takano, J., Nilsson, P., Itohara, S., Iwata, N., & Saido, T. C. (2014) · Nature Neuroscience · doi:10.1038/nn.3697 · Cited by 1,366 · cited 5×
“31,32 However, we observed a lower discrimination index in the NOR test in 22-month-old App NL-F mice than in 6-month-old App NL-G-F mice (Figures 4A and 6A).”
InfluentialSelf-citationGamma frequency entrainment attenuates amyloid load and modifies microglia
Iaccarino, H. F., Singer, A. C., Martorell, A. J., Rudenko, A., Gao, F., Gillingham, T. Z., Mathys, H., Seo, J., Kritskiy, O., Abdurrob, F., et al. (2016) · Nature · doi:10.1038/nature20587 · Cited by 1,328
Wyss-Coray (2006) · doi:10.1038/nm1484 · Cited by 1,284
Spatial Transcriptomics and In Situ Sequencing to Study Alzheimer’s Disease
Chen, W.-T., Lu, A., Craessaerts, K., Pavie, B., Sala Frigerio, C., Corthout, N., Qian, X., Laláková, J., Kühnemund, M., Voytyuk, I., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.038 · Cited by 949 · cited 1×
“41 With this in mind, it is interesting that one feature that was robustly affected in App NL-G-F and App NL-F mice in our study was astrocyte activation in the close vicinity of A b plaques (Figures 5D – 5F, 7D – 7F, and 8).”
Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model
Dodart, J.-C., Bales, K. R., Gannon, K. S., Greene, S. J., DeMattos, R. B., Mathis, C., DeLong, C. A., Wu, S., Wu, X., Holtzman, D. M., et al. (2002) · Nature Neuroscience · doi:10.1038/nn842 · Cited by 858 · cited 1×
“43,44 The re-sults for rh Bri2 BRICHOS R221E and monoclonal antibodies have Molecular Therapy been obtained using different treatment schemes and different AD mouse models, and they can therefore not be directly compared.”
Multi-sensory Gamma Stimulation Ameliorates Alzheimer’s-Associated Pathology and Improves Cognition
Martorell, A. J., Paulson, A. L., Suk, H.-J., Abdurrob, F., Drummond, G. T., Guan, W., Young, J. Z., Kim, D. N.-W., Kritskiy, O., Barker, S. J., et al. (2019) · Cell · doi:10.1016/j.cell.2019.02.014 · Cited by 798
Clinical trials of new drugs for Alzheimer disease
Huang, L.-K., Chao, S.-P., & Hu, C.-J. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-019-0609-7 · Cited by 702 · cited 1×
“9 There is a high rate of failure of compounds developed for AD, and many tested compounds, in particular antibodies, have poor permeability over the blood-brain barrier (BBB), 10 but recently a monoclonal antibody was approved by the US Food and Drug Administration for AD treatment.”
Microglia, neuroinflammation, and beta-amyloid protein in Alzheimer’s disease
Cai, Z., Hussain, M. D., & Yan, L.-J. (2014) · International Journal of Neuroscience · doi:10.3109/00207454.2013.833510 · Cited by 583
Anti-Amyloid-β Monoclonal Antibodies for Alzheimer’s Disease: Pitfalls and Promise
van Dyck, C. H. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.08.010 · Cited by 568 · cited 1×
“43,44 The re-sults for rh Bri2 BRICHOS R221E and monoclonal antibodies have Molecular Therapy been obtained using different treatment schemes and different AD mouse models, and they can therefore not be directly compared.”
Astrogliosis: An integral player in the pathogenesis of Alzheimer's disease
Osborn, L. M., Kamphuis, W., Wadman, W. J., & Hol, E. M. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.01.001 · Cited by 312
The identity and function of microglia in neurodegeneration
Song, W. M., & Colonna, M. (2018) · Nature Immunology · doi:10.1038/s41590-018-0212-1 · Cited by 308 · cited 1×
“Evidence from animal and human studies suggests involvement of microglia in the pathological cascade of AD, and we used the microglial activation marker ionized calcium-binding adapter molecule 1 (Iba1) 35,36 to analyze rh Bri2 BRICHOS R221E-and PBS-treated App NL-G-F mice.”
Cognitive deficits in single App knock-in mouse models
Masuda, A., Kobayashi, Y., Kogo, N., Saito, T., Saido, T. C., & Itohara, S. (2016) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2016.07.001 · Cited by 248 · cited 2×
“31,32 However, we observed a lower discrimination index in the NOR test in 22-month-old App NL-F mice than in 6-month-old App NL-G-F mice (Figures 4A and 6A).”
Bivalent Brain Shuttle Increases Antibody Uptake by Monovalent Binding to the Transferrin Receptor
Hultqvist, G., Syvänen, S., Fang, X. T., Lannfelt, L., & Sehlin, D. (2017) · Theranostics · doi:10.7150/thno.17155 · Cited by 224
Hardy, J. (2017) · The FEBS Journal · doi:10.1111/febs.14004 · Cited by 153 · cited 6×
“…APP and abnormal A b metabolism have been proposed to be two of the main causes of AD, supported by the mutations that cause increased A b production, in particular of the aggregation-prone A b 42, leading to early-onset AD, 6 whereas a mutation that lowers A b production has a preventive effect.”
InfluentialMicroglial motility in Alzheimer’s disease and after Aβ42 immunotherapy: a human post-mortem study
Franco-Bocanegra, D. K., George, B., Lau, L. C., Holmes, C., Nicoll, J. A. R., & Boche, D. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0828-x · Cited by 64 · cited 1×
“Evidence from animal and human studies suggests involvement of microglia in the pathological cascade of AD, and we used the microglial activation marker ionized calcium-binding adapter molecule 1 (Iba1) 35,36 to analyze rh Bri2 BRICHOS R221E-and PBS-treated App NL-G-F mice.”
Kunkle, B., Grenier-Boley, B., Sims, R., Bis, J., Naj, A., Boland, A., Vronskaya, M., van der Lee, S., Amlie-Wolf, A., Bellenguez, C., et al. (2018) · doi:10.1101/294629 · Cited by 35
Research works printed but not linked: 32
- Benson, 2018, Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee, Amyloid., 25, 215, 10.1080/13506129.2018.1549825 · DOI · Paper page
- Kim, 2009, Bridging physiology and pathology in AD, Cell, 137, 997, 10.1016/j.cell.2009.05.042 · DOI
- Hardy, 1992, Alzheimer's disease: the amyloid cascade hypothesis, Science, 256, 184, 10.1126/science.1566067 · DOI · Paper page
- Aschenbrenner, 2021, Controversial approval of new drug to treat alzheimer's disease, Am. J. Nurs., 121, 22
- Balchin, 2020, Recent advances in understanding catalysis of protein folding by molecular chaperones, FEBS Lett., 594, 2770, 10.1002/1873-3468.13844 · DOI · Paper page
- Kampinga, 2016, Heat shock proteins as potential targets for protective strategies in neurodegeneration, Lancet Neurol., 15, 748, 10.1016/S1474-4422(16)00099-5 · DOI · Paper page
- Sánchez-Pulido, 2002, BRICHOS: a conserved domain in proteins associated with dementia, respiratory distress and cancer, Trends Biochem. Sci., 27, 329, 10.1016/S0968-0004(02)02134-5 · DOI · Paper page
- Hedlund, 2009, BRICHOS - a superfamily of multidomain proteins with diverse functions, BMC Res. Notes, 2, 180, 10.1186/1756-0500-2-180 · DOI
- Nerelius, 2008, Mutations linked to interstitial lung disease can abrogate anti-amyloid function of prosurfactant protein C, Biochem. J., 416, 201, 10.1042/BJ20080981 · DOI
- Willander, 2012, High-resolution structure of a BRICHOS domain and its implications for anti-amyloid chaperone activity on lung surfactant protein C, Proc. Natl. Acad. Sci. USA, 109, 2325, 10.1073/pnas.1114740109 · DOI
- Buxbaum, 2017, Transthyretin and BRICHOS: the paradox of amyloidogenic proteins with anti-amyloidogenic activity for Aβ in the central nervous system, Front. Neurosci., 11, 119, 10.3389/fnins.2017.00119 · DOI
- Kurudenkandy, 2014, Amyloid-beta-induced action potential desynchronization and degradation of hippocampal gamma oscillations is prevented by interference with peptide conformation change and aggregation, J. Neurosci., 34, 11416, 10.1523/JNEUROSCI.1195-14.2014 · DOI · Paper page
- Nerelius, 2009, Anti-amyloid activity of the C-terminal domain of proSP-C against amyloid beta-peptide and medin, Biochemistry, 48, 3778, 10.1021/bi900135c · DOI
- Poska, 2016, Dementia related Bri2 BRICHOS is a versatile molecular chaperone that efficiently inhibits Abeta42 toxicity in Drosophila, Biochem. J., 473, 3683, 10.1042/BCJ20160277 · DOI
- Hermansson, 2014, The chaperone domain BRICHOS prevents CNS toxicity of amyloid-beta peptide in Drosophila melanogaster, Dis. Model. Mech., 7, 659
- Arosio, 2016, Kinetic analysis reveals the diversity of microscopic mechanisms through which molecular chaperones suppress amyloid formation, Nat. Commun., 7, 10948, 10.1038/ncomms10948 · DOI · Paper page
- Cohen, 2015, A molecular chaperone breaks the catalytic cycle that generates toxic Abeta oligomers, Nat. Struct. Mol. Biol., 22, 207, 10.1038/nsmb.2971 · DOI · Paper page
- Leppert, 2021, Smallest secondary nucleation competent abeta aggregates probed by an ATP-independent molecular chaperone domain, Biochemistry, 60, 678, 10.1021/acs.biochem.1c00003 · DOI
- Andrade-Talavera, 2021, Bri2 BRICHOS chaperone rescues impaired fast-spiking interneuron behavior and neuronal network dynamics in an AD mouse model in vitro, Neurobiol. Dis., 159, 105514, 10.1016/j.nbd.2021.105514 · DOI
- Galan-Acosta, 2020, Recombinant BRICHOS chaperone domains delivered to mouse brain parenchyma by focused ultrasound and microbubbles are internalized by hippocampal and cortical neurons, Mol. Cell. Neurosci., 105, 103498, 10.1016/j.mcn.2020.103498 · DOI
- Tambaro, 2019, Blood-brain and blood-cerebrospinal fluid passage of BRICHOS domains from two molecular chaperones in mice, J. Biol. Chem., 294, 2606, 10.1074/jbc.RA118.004538 · DOI
- Chen, 2017, Bri2 BRICHOS client specificity and chaperone activity are governed by assembly state, Nat. Commun., 8, 2081, 10.1038/s41467-017-02056-4 · DOI · Paper page
- Chen, 2020, Augmentation of Bri2 molecular chaperone activity against amyloid-beta reduces neurotoxicity in mouse hippocampus in vitro, Commun. Biol., 3, 32, 10.1038/s42003-020-0757-z · DOI · Paper page
- Shah, 2018, Spatial reversal learning defect coincides with hypersynchronous telencephalic BOLD functional connectivity in APP(NL-F/NL-F) knock-in mice, Sci. Rep., 8, 6264, 10.1038/s41598-018-24657-9 · DOI · Paper page
- Abelein, 2020, High-yield production of amyloid-beta peptide enabled by a customized spider silk domain, Sci. Rep., 10, 235, 10.1038/s41598-019-57143-x · DOI · Paper page
- Olsen, 2018, Astroglial responses to amyloid-beta progression in a mouse model of alzheimer's disease, Mol. Imaging Biol., 20, 605, 10.1007/s11307-017-1153-z · DOI
- Linse, 2020, Kinetic fingerprints differentiate the mechanisms of action of anti-Abeta antibodies, Nat. Struct. Mol. Biol., 27, 1125, 10.1038/s41594-020-0505-6 · DOI · Paper page
- Ribary, 1991, Magnetic field tomography of coherent thalamocortical 40-Hz oscillations in humans, Proc. Natl. Acad. Sci. USA, 88, 11037, 10.1073/pnas.88.24.11037 · DOI · Paper page
- Arroyo-García, 2021, Impaired spike-gamma coupling of area CA3 fast-spiking interneurons as the earliest functional impairment in the App(NL-G-F) mouse model of Alzheimer's disease, Mol. Psychiatry, 26, 5557, 10.1038/s41380-021-01257-0 · DOI · Paper page
- Kronqvist, 2017, Efficient protein production inspired by how spiders make silk, Nat. Commun., 8, 15504, 10.1038/ncomms15504 · DOI
- Zhong, 2022, Amyloid fibril formation of Arctic amyloid-β 1–42 peptide is efficiently inhibited by the BRICHOS domain, ACS Chem. Biol., 17, 2201, 10.1021/acschembio.2c00344 · DOI
- Bates, 2015, Fitting linear mixed-effects models using lme4, J. Stat. Softw., 67, 1
Cited by
Functional BRI2-TREM2 interactions in microglia: implications for Alzheimer’s and related dementias
Yin, T., Yesiltepe, M., & D’Adamio, L. (2024) · EMBO Reports · doi:10.1038/s44319-024-00077-x · Cited by 15
“Interestingly, a single point mutation, R221E, within the BRI2 BRICHOS domain has been shown to favor the monomeric form and exhibits greater ef fi cacy than wild-type BRI2 BRICHOS in mitigating A β 42-mediated neurotoxicity in mouse hippocampal slices (Chen et al, 2020; Manchanda et al, 2023).”
Metadata
- Authors
- Manchanda, S., Galan-Acosta, L., Abelein, A., Tambaro, S., Chen, G., Nilsson, P., & Johansson, J.
- ORCID
- Johansson, Jan
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2023-02
- Volume
- 31
- Issue
- 2
- Pages
- 487-502
- ISSN
- 1525-0016
- Cited by
- 38
- References
- 20
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Funders
- Svenska Sällskapet för Medicinsk Forskning
- Alzheimerfonden
- Loo och Hans Ostermans Stiftelse för Medicinsk Forskning
- Torsten Söderbergs Stiftelse
- Gun och Bertil Stohnes Stiftelse
- Vetenskapsrådet (2020-02434, 2016-01967)
- Hjärnfonden
- Karolinska Institutet
- Bertil Hållstens Forskningsstiftelse
- Center for Innovative Medicine
- Stiftelsen för Gamla Tjänarinnor
- Petrus och Augusta Hedlunds Stiftelse
- Magnus Bergvalls Stiftelse
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.